What insurance plans does Leslie T. Busby, MD accept?

Aetna, Anthem BCBS Colorado, Apostrophe Health, b SMART, Carrum, Cigna, Colorado Access, First Health, Humana Medicare Advantage, *Kaiser (depending on market), Medicare, Medicaid, Multiplan/PHCS, Optum Health / Optum Care CO, PHPprime, Rocky Mountain Health Plans Medicaid Prime, CHP+, Valley, Monument Tier 2 & CO Doctors Plan, SMS, TRICARE/HealthNET, United Healthcare

Leslie T. Busby, MD

Medical Oncologist / Hematologist

Not accepting new patients at this time

View Awards

View Awards

Skip to section

Announcements

Dr. Busby is moving to a new role of Chief Medical Officer for The US Oncology Network as of July 1, 2025. He is no longer accepting new patients.

Provider Biography

Dr. Leslie Busby is a board-certified medical oncologist and hematologist. His practice expertise includes blood cancers, such as leukemia, lymphoma, and multiple myeloma, as well as nonmalignant blood disorders such as anemia and coagulation abnormalities. He is also a general medical oncologist treating colorectal, lung, genitourinary, and gastrointestinal cancers.

Adopting a collaborative approach to care, Dr. Busby is a member of weekly gastrointestinal, neurological, breast, general, and hematology tumor boards, presenting and reviewing cases with a multi-disciplinary team of cancer specialists such as surgeons, radiologists, pathologists, and radiation oncologists. His commitment to advancing cutting-edge cancer treatment in the community is the hallmark of his practice. This joint effort ensures his patients are given the best option for treatment tailored to their specific diagnosis.

As the chairman of the US Oncology Network Pharmacy & Therapeutics Committee, Dr. Busby is directly involved helping practices like Rocky Mountain Cancer Centers provide safe and efficient therapy in their practices and bringing the most recent advances in cancer therapies to patients.

Provider Specialties

Blood Cancers
- Leukemia
- Lymphoma
- Multiple Myeloma
Gastrointestinal Cancers
- Anal Cancer
- Colorectal Cancer
- Esophageal Cancer
- Liver Cancer
- Pancreatic Cancer
- Stomach Cancer
Lung Cancer

Care Philosophy

I believe that most patients get overall better care when treated by physicians who live and work in the same community. There have been incredible advancements in the treatment of cancer, but even more important than whether a cancer can be treated is how to treat the patient. What are her goals and needs? What sort of activities does he like to do? I relish the challenge to balance helping my patients live as long as possible, while continuing to be as active as they can.

Benign blood disorders can also be life-altering and I want to help patients manage these problems as best as we can. Patient safety is an important goal of mine and is why I have been active with pharmacy & therapeutics committees since I started practicing in 2002. In my role at the US Oncology Network Pharmacy and Therapeutics Committee, I work closely with pharmacists and physicians across the country to help practices continually improve their systems to provide better and safer care.

Care Team

Laurie Shumaker
View Profile

Locations

4715 Arapahoe Ave.
Boulder, CO 80303

303-385-2000

Fax: 303-267-4419

8:00am - 5:00pm | M-F

Request Appointment View Details

Skip to section

Education

Fellowship

Medical Oncology & Hematology, University of Utah, Salt Lake City, UT

Residency

Internal Medicine, University of Missouri-Kansas City, Kansas City, MO

Medical School

University of Nevada, School of Medicine, Reno, NV

Board Certifications

Hematology
Medical Oncology

Memberships

American Society of Clinical Oncology
American Society of Hematology
Boulder Valley Care Network Clinical Quality Improvement and Credentialing Committee
Rocky Mountain Cancer Centers Pharmacy & Therapeutics Committee
US Oncology Network Pharmacy & Therapeutics Committee, Chairman
US Oncology Network Pharmacy & Therapeutics Executive Committee
US Oncology Network Pharmacy & Therapeutics GPO Sub-Committee, Co-Chairman

Articles

RMCC Physicians Honored in 5280 Magazine’s “Top Docs”2025 List

1 min read

Progress Treating Lung Cancer With ALK-Positive Mutations — The Drug Lorlatinib Shows Major Benefit For Progression Free Survival

1 min read

Videos

Publications

Show Publications
- Wilfong L, MD, Ginsburg A, PharmD, Hoverman JR, MD, Burke JM, MD, Busby LT, MD, Hseih A, PharmD, Konduri K, MD, and Neubauer MA, MD: Treatment Pathways for First-Line Metastatic Non-Small Cell Lung Cancer: Cost and Survival. J Clin Pathways October 2020;6(8):52-57.